EZH2 and neoplasm: Taken together, these results show that the combined use of EZH1/2 dual inhibitor may enhance the anti-tumor effects of sorafenib by canceling sorafenib-induced activation of EZH2 and additional inhibition of EZH1 (Fig. 7).